Anna Panighini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Panighini has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Fabbri
Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy
1 shared publication - Carla Fiorentini
Association for Research on Integrative Oncology Therapies (ARTOI), Via Ludovico Micara, 73, 00165 Rome, Italy
1 shared publication - Chiara Cerri
CNR Neuroscience Institute, Via Moruzzi,1 56100 Pisa, Italy
1 shared publication - Eleonora Vannini
CNR Institute of Neuroscience, Pisa, Italy
1 shared publication - Enrico Pracucci
National Enterprise for nanoScience and nanoTechnology (NEST), Istituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR) and Scuola Normale Superiore Pisa, Pisa, Italy
1 shared publication - Mario Costa
Neuroscience Institute, National Research Council (CNR), via G. Moruzzi 1, 56124 Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 18 June 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 449
The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model
Glioblastomas are largely unresponsive to all available treatments and there is therefore an urgent need for novel therapeutics. Here we have probed the antineoplastic effects of a bacterial protein toxin, the cytotoxic necrotizing factor 1 (CNF1), in the syngenic GL261 glioma cell model. CNF1 produces a long-lasting activation of Rho GTPases, with consequent blockade of cytodieresis in proliferating cells and promotion of neuron health and plasticity.
- 18 June 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 449
Open AccessThe bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model
Glioblastomas are largely unresponsive to all available treatments and there is therefore an urgent need for novel therapeutics. Here we have probed the antineoplastic effects of a bacterial protein toxin, the cytotoxic necrotizing factor 1 (CNF1), in the syngenic GL261 glioma cell model. CNF1 produces a long-lasting activation of Rho GTPases, with consequent blockade of cytodieresis in proliferating cells and promotion of neuron health and plasticity.